Brian Finan

机构：Eli Lilly (United States), Novo Nordisk (United States) · ORCID：0000-0002-6467-0447

发表论文 140 篇 · 总被引 10997 次 · h-index 49

代表论文

• The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling (2021 · Cell Metabolism · 被引 321)
• GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications (2023 · Cell Metabolism · 被引 149)
• Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022 · Molecular Metabolism · 被引 147)
• Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise (2021 · Nature Communications · 被引 135)
• The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets (2023 · Nature Metabolism · 被引 122)
• 100 years of glucagon and 100 more (2023 · Diabetologia · 被引 116)